Compare Adaptive Biotechnologies Corp (ADPT) vs Wipro Limited (WIT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Wipro Limited — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Wipro Limited trades at $1.83 (market cap $18.14B). The key difference: Wipro Limited is far larger — about 5.4× Adaptive Biotechnologies Corp's market cap, and Wipro Limited pays a 10.37% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | WIT | |
|---|---|---|
Market Cap | $3.33B | $18.14B |
Sector | Health | Technology |
52-Week High | $22.37 | $3.09 |
52-Week Low | $10.24 | $1.82 |
Enterprise Value | $3.19B | $14.53B |
Dividend Yield | — | 10.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
WIT trades at $1.85, down 2.12% today, with a bearish technical signal from moving averages. The company reported revenue of $890.88B in 2025 with a net income margin of 14.25% and a P/E ratio of 13.82. Recent earnings have missed estimates for three consecutive quarters, and analyst sentiment is mixed with a Hold consensus. News highlights include AI partnerships and a weak Q2 2026 revenue outlook.
The outlook is cautious due to near-term revenue pressure and earnings misses, though valuation appears reasonable. Risks include client spending caution and competitive pressures. Upside may depend on AI-driven growth initiatives and large deal execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
